Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

Autor:	Hurvitz, Sara A *, Bardia, Aditya, Quiroga, Vanesa, Park, Yeon Hee, Blancas, Isabel, Alonso-Romero, José Luis, Vasiliev, Aleksandr, Adamchuk, Hryhoriy, Salgado, Marcelo, Yardley, Denise A, Berzoy, Oleksandr, Zamora-Auñón, Pilar, Chan, David, Spera, Gonzalo, Xue, Cloris, Ferreira, Erika, Badovinac Crnjevic, Tanja, Pérez-Moreno, Pablo Diego, López-Valverde, Vanesa, Steinseifer, Jutta, Fernando, Tharu M, Moore, Heather M, Fasching, Peter A
Zdroj:	In The Lancet Oncology September 2023 24(9):1029-1041
Databáze:	ScienceDirect
Externí odkaz:	Zobrazit plný text záznamu